Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2023-02-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for Immunotech Biopharm Ltd, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes and confirmations rather than financial performance, earnings, or management commentary. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory submission related to share capital movements and confirmations, fitting the category of a Regulatory Filing (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is a formal regulatory return rather than a simple announcement. The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2023-02-03 English
EXTENSION OF LONG STOP DATE IN RELATION TO THE SUBSCRIPTION AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement from Immunotech Biopharm Ltd regarding the extension of the long stop date related to a Subscription Agreement for the proposed issue of Convertible Bonds. It references previous announcements and a circular but does not contain financial statements or detailed financial data. The content focuses on financing activity, specifically the extension of a deadline related to a capital raising transaction. The document length is short (2292 characters) and it is clearly an update on financing terms rather than a full report or detailed financial disclosure. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-01-26 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 11 JANUARY 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement from Immunotech Biopharm Ltd regarding the poll results of an Extraordinary General Meeting (EGM) held on 11 January 2023. It details the voting outcomes on resolutions related to a subscription agreement and convertible bonds. The text includes specific voting numbers and percentages, references to the EGM notice and circular, and confirms the passing of the resolution by shareholders. There is no detailed financial data or comprehensive report content, but rather the official results of a shareholder vote at a general meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 5,482 characters, which is sufficient for a detailed voting result announcement but not a full report. Therefore, the correct classification is DVA with high confidence.
2023-01-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for Immunotech Biopharm Ltd, specifically focusing on authorized and issued share capital, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, reporting share capital and share option movements for the month ended 31 December 2022. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a formal monthly return submission to the exchange rather than a standalone capital change announcement.
2023-01-06 English
TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE
Remuneration Information Classification · 95% confidence The document is titled 'Terms of Reference of the Remuneration Committee' and details the purpose, composition, meetings, authority, and responsibilities of the remuneration committee of Immunotech Biopharm Ltd. It focuses on the committee's role in recommending and overseeing remuneration policies for directors and senior management, including share schemes and compensation. There are no financial statements, earnings data, or report publication announcements. The content is governance-related, specifically about remuneration policies and committee procedures, which aligns with the definition of Remuneration Information filings. The document is substantive and not a brief announcement or certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2022-12-30 English
VOLUNTARY ANNOUNCEMENT RECEIPT OF THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE DENOCABTAGENE CILOLEUCEL INJECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Immunotech Biopharm Ltd regarding the receipt of an acceptance notice for an Investigational New Drug Application from a regulatory authority. It provides detailed information about the drug, its background, and the company's business focus. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a regulatory milestone related to drug development, not a financial report, management change, or shareholder meeting material. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.